← Leaderboards
Melina Rae Kibbe
Northwestern University At Chicago
$9,200,692
Attributed
$14,732,593
Total exposure
11
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2006–25$2.5M$1.9M$1.3M$625K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,732,593 · 8
VA$0 · 3
By mechanism
R01$13,309,724 · 5
K08$632,812 · 1
T32$489,741 · 1
R43$300,316 · 1
I01$0 · 3
Top collaborators
- Samuel I Stupp8 shared
- Guillermo A Ameer6 shared
- Nick Dimitrios Tsihlis3 shared
- William H Pearce2 shared
- Antonio Roy Webb1 shared
Most similar at Northwestern University At Chicago
Same institution · by research overlap
- Ramille N Shah$1,632,424
- Maya Srikanth Graham$882,803
- John Gregory Cooper$186,327
- Nicholas Stephanopoulos$2,819,935
- Stephany Standley$132,650
Others in their field
Top investigators on “Blood Vessels”
- Sonia M Thomas · Research Triangle Institute$353,402,726
- Tracy L Nolen · Research Triangle Institute$353,402,726
- Charles Decarli · University Of California At Davis$66,498,201
- Josef Coresh · New York University School Of Medicine$63,693,760
- Sterling C Johnson · St. Joseph'S Hospital And Medical Center$62,000,770
- Robert P Kimberly · University Of Alabama At Birmingham$56,093,149
Research focus
Blood VesselsHyperplasiaInnovationProceduresAtherosclerosisSafetyPreventBypassInflammationIn VitroIn VivoSmooth Muscle MyocytesArteriesNitric OxideThrombosisRestenosisInjuryUnited StatesBloodFamily SuidaeCellsBiomaterial CompatibilityBalloon AngioplastyOperative Surgical Procedures
Grant awards (41)
Development of a multi-modal targeted nanotherapeutic to prevent restenosis in an atherosclerotic environment$635,074
R01 · FY2025 · HL
Development of a multi-modal targeted nanotherapeutic to prevent restenosis in an atherosclerotic environment$618,998
R01 · FY2024 · HL · contact PI
Development of a multi-modal targeted nanotherapeutic to prevent restenosis in an atherosclerotic environment$626,054
R01 · FY2023 · HL · contact PI
Development of a multi-modal targeted nanotherapeutic to prevent restenosis in an atherosclerotic environment$664,358
R01 · FY2022 · HL · contact PI
A Novel Endovascular Approach to Remove Atherosclerotic Plaque Lesions In Situ$635,599
R01 · FY2022 · HL · contact PI
A Novel Endovascular Approach to Remove Atherosclerotic Plaque Lesions In Situ$711,711
R01 · FY2021 · HL · contact PI
Novel in situ custom biodegradable drug-eluting stents for endovascular surgery$0
I01 · FY2021 · VA · contact PI
A Novel Endovascular Approach to Remove Atherosclerotic Plaque Lesions In Situ$717,432
R01 · FY2020 · HL · contact PI
Novel in situ custom biodegradable drug-eluting stents for endovascular surgery$0
I01 · FY2020 · VA · contact PI
A Novel Endovascular Approach to Remove Atherosclerotic Plaque Lesions In Situ$755,738
R01 · FY2019 · HL · contact PI
Bioengineering Catalytically Active Grafts for Vascular Surgery$0
I01 · FY2019 · VA · contact PI
Bioengineering Catalytically Active Grafts for Vascular Surgery$0
I01 · FY2018 · VA · contact PI
Bioengineering Catalytically Active Grafts for Vascular Surgery$0
I01 · FY2017 · VA · contact PI
Novel Vehicles for Targeted Cardiovascular Repair$1,102,604
R01 · FY2016 · HL · contact PI
Preclinical Investigation of a Bioengineered Vascular Graft$413,054
R01 · FY2016 · EB
Preclinical Investigation of a Bioengineered Vascular Graft$100,000
R01 · FY2016 · EB
Bioengineering Catalytically Active Grafts for Vascular Surgery$0
I01 · FY2016 · VA · contact PI
Novel Vehicles for Targeted Cardiovascular Repair$1,103,789
R01 · FY2015 · HL · contact PI
Preclinical Investigation of a Bioengineered Vascular Graft$418,612
R01 · FY2015 · EB
NO inhibits arterial injury after vascular procedures via adventitial stem cells$375,531
R01 · FY2015 · HL · contact PI
Vascular Surgery Scientist Training Program$282,951
T32 · FY2015 · HL
Bioengineering Catalytically Active Grafts for Vascular Surgery$0
I01 · FY2015 · VA · contact PI
Novel Vehicles for Targeted Cardiovascular Repair$1,070,603
R01 · FY2014 · HL · contact PI
Preclinical Investigation of a Bioengineered Vascular Graft$424,691
R01 · FY2014 · EB
NO inhibits arterial injury after vascular procedures via adventitial stem cells$373,625
R01 · FY2014 · HL · contact PI
Vascular Surgery Scientist Training Program$206,790
T32 · FY2014 · HL
Novel Vehicles for Targeted Cardiovascular Repair$999,212
R01 · FY2013 · HL · contact PI
Preclinical Investigation of a Bioengineered Vascular Graft$437,589
R01 · FY2013 · EB
NO inhibits arterial injury after vascular procedures via adventitial stem cells$362,950
R01 · FY2013 · HL · contact PI
Inhibition of Neointimal Hyperplasia Following Vascular Surgery in Diabetes$0
I01 · FY2013 · VA · contact PI
NO inhibits arterial injury after vascular procedures via adventitial stem cells$381,250
R01 · FY2012 · HL · contact PI
Inhibition of Neointimal Hyperplasia Following Vascular Surgery in Diabetes$0
I01 · FY2012 · VA · contact PI
NO inhibits arterial injury after vascular procedures via adventitial stem cells$381,250
R01 · FY2011 · HL · contact PI
Inhibition of Neointimal Hyperplasia Following Vascular Surgery in Diabetes$0
I01 · FY2011 · VA · contact PI
Nitric oxide eluting therapies for vascular surgery$127,358
K08 · FY2010 · HL · contact PI
Controlled Release Vascular Grafts$300,316
R43 · FY2009 · HL
Nitric oxide eluting therapies for vascular surgery$127,358
K08 · FY2009 · HL · contact PI
Inhibition of Neointimal Hyperplasia Following Vascular Surgery in Diabetes$0
I01 · FY2009 · VA · contact PI
Nitric oxide eluting therapies for vascular surgery$127,358
K08 · FY2008 · HL · contact PI
Nitric oxide eluting therapies for vascular surgery$127,358
K08 · FY2007 · HL · contact PI
Nitric oxide eluting therapies for vascular surgery$123,380
K08 · FY2006 · HL · contact PI